Latest news with #PMX
Yahoo
3 days ago
- Business
- Yahoo
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held yesterday on June 5, 2025 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the "Circular") to its Shareholders were approved. Results of the matters voted on at the Meeting are set out below. Election of Directors Spectral's seven director nominees were elected: Nominee Votes For (percent) Votes Withheld (percent) Jan D'Alvise 99.78% 0.22% Jun Hayakawa 99.79% 0.21% Chris Seto 89.39% 10.61% William Stevens 99.50% 0.50% Paul Walker 97.67% 2.33% David W. Feigal, Jr. 99.67% 0.33% Cristiano Franzi 99.78% 0.22% Appointment of Auditors MNP LLP, Chartered Accountants, was re-appointed as auditor of Spectral. Votes For: 99.95% Votes Withheld: 0.05% About Spectral Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively over 360,000 times to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year. The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis The trial methods are detailed in 'Bayesian methods: a potential path forward for sepsis trials'. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the company's ability to raise capital and the availability of funds and resources to pursue R&D projects, the recruitment of additional clinical trial sites, the rate of patient enrollment, the successful and timely completion of clinical studies, the success of Baxter's commercialization efforts, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For further information, please contact: Ali MahdaviCapital Markets & Investor RelationsSpinnaker Capital Markets Inc.416-962-3300am@
Focus Malaysia
3 days ago
- Politics
- Focus Malaysia
Boycott PKR in GE16 greets Nurul Izzah's victory; grassroots foresee rot from prevalent family ties
WHAT an anti-climax! Instead of being jubilant, many Reformasi diehards who have been vital lynchpins to PKR's very existence have vowed to disassociate themselves from the party which they claimed have switched to self-destruction mode following Nurul Izzah Anwar's victory against incumbent Datuk Seri Rafizi Ramli in the PKR deputy presidency race. This came about as Malaysiakini broke the news citing party election committee chairperson Datuk Seri Dr Zaliha Mustafa as having announced that Nurul Izzah has toppled the Economy Minister with 9,803 votes. Tak rasmi: Rafizi kalah pemilihan PKR — Malaysiakini (BM) (@mkini_bm) May 23, 2025 Although Dr Zaliha did not state the number of votes polled by Rafizi, it was revealed in the party's Borang Keputusan (Borang 14) that the Pandan MP garnered only 3,866 votes which means the eldest daughter of Prime Minister Datuk Seri Anwar Ibrahim won by an overwhelming majority of 5,937 votes or 60.6% margin. Sarcasm of sorts filled the news portal's comments section with the most popular being 'hopefully later, Nurul Izzah's other sisters will contest for the party's vice-presidency'. Another insinuated that her younger siblings may even vie for head of PKR's youth wing or even PMX's son-in-law (Nurul Izzah's husband) as a member of the party's Central Leadership Council (MPP). On a more serious note, many anticipated the party to languish from nepotism, hence wanting to disassociate themselves from PKR come the 16th General Election (GE16). Boycotting the party or abstain from voting in GE16 which means turning their back to the PKR-led Pakatan Harapan (PH) coalition would point to PMX being a one-term premier, insinuated one disgruntled grassroot member. One commenter expressed disbelief at how PMX used to hit out at twice former premier Tun Dr Mahathir Mohamad for promoting his son Datuk Seri Mukhriz Mahathir as his successor yet he (PMX) himself is doing the exact same thing now. Another contended that it has become clear why prominent leaders like Datuk Ezam Mohd Nor (a founding PJR member) or Datuk Seri Mohamed Azmin Ali (former deputy president) eventually left the party to join the opposition while one is bracing for PKR/ruling PH coalition to come under fire from their own supporters. 'There's no need to await the official results for the writing was already on the wall … I wish PH a happy return to being an opposition … confirm you shall be a flop in GE16; you've lost my vote,' fumed one supposedly staunch PKR backer. While it may be too soon to gauge the anticipated devastation, one 'overseas-stationed' commenter summed up that his entire family members who are still residing in Malaysia will no longer vote for Nurul Izzah, her father, her mother 'or the party now gasping under the weight of your entitlement!' – May 24, 2025
Focus Malaysia
3 days ago
- Politics
- Focus Malaysia
Siti Kasim: Maybe hard for PMX to gain immunity from Federal Court judging from Najib's precedent
THERE is already a precedent whereby the Federal Court had previously ruled against now incarcerated former premier Datuk Seri Najib Razak to be granted immunity from the extraordinary claim (civil suit) filed against the Malaysian Government by then Petaling Jaya Utara MP Tony Pua in January 2017. Premised on the common law tort of misfeasance in public office, the thrust of the claim was that Najib had committed misfeasance in public office in relation to the sovereign fund 1MDB. It was alleged that the then 10-term Pekan MP had abused his public office by personally benefitting from the receipt of monies from the 1MDB fund. Against such backdrop, human rights activist and lawyer Siti Kasim opined that Prime Minister Datuk Seri Anwar Ibrahim is liable for the civil suit on se*ual harassment filed against him by his former research assistant Yusoff Rawther four years ago. 'Recall that Pua lost his case at both the High Court and Appeal Court levels but the Federal Court ruled that Najib can be charged with misfeasance in public office given the PM or any minister for the matter are regarded as civil servants,' she recounted on her latest YouTube rant. 'Moreover, in my personal opinion a PM should not be exempted from any civil suit in his personal capacity … After all, the civil suit filed by Yusoff revolves around sexual assault on him prior to him having assumed his PM office.' Added the Orang Asli advocate: 'Going by the precedent set by Najib's case, Anwar can be sued on grounds that a PM doesn't enjoy immunity but it seems that Yusoff has to wait for a few more years before the hearing of his civil suit can materialise. 'He may now have to wait for the decision of the Federal Court on Anwar's immunity claim first … We can only pray that justice shall prevail for the righteous party.' PMX seeks immunity For context PMX had on yesterday (May 27) sought the Federal Court ruling if he should be granted immunity from the civil suit filed by Yusoff prior to him taking office on Nov 24, 2022. The 31-year-old grandson of the late Penang consumer advocate SM Mohamed Idris had filed his civil suit in July 2021 in which he alleged that Anwar had sexually assaulted him on Oct 2, 2018 at Anwar's residence in Segambut, Kuala Lumpur. In his countersuit, Anwar claimed that Yusoff's allegation of sexual harassment against him is unfounded as he was entertaining his family and friends at his residence. The KL High Court last year fixed the trial to be heard from June 16 to 19 and June 23 to 25. However, Yusoff found himself charged in the KL High Court on Dec 5 last year here with trafficking in 305gm of cannabis in addition to having in his possession two imitation pistols to which he pleaded not guilty. Framed under Section 39B(1)(a) of the Dangerous Drugs Act 1952, the drug charge which is punishable under Section 39B(2) of the same Act, provides life imprisonment and whipping of not less than 12 lashes upon conviction. 'Throughout his drug and pistol trial, Yusoff has incessantly claimed that he has been trapped and framed by people in the authority who holds grudges against him for his civil suit,' observed Siti Kasim. 'Additionally, Yusoff also filed two police reports by calling for investigation against Anwar's former political secretary Datuk Farhash Wafa Salvador Rizal Mubarak but the police have yet to act on the reports filed by Yusoff.' – May 28, 2025 Main image credit: SK Studio/YouTube
Focus Malaysia
3 days ago
- Politics
- Focus Malaysia
High court judge Roz Mawar praised for sound, solid judgment in denying PMX's immunity bid
TWO prominent lawyers are impressed with the grounds of Kuala Lumpur High Court judge Roz Mawar Rozain in rejecting Prime Minister Datuk Seri Anwar Ibrahim's bid to suspend the civil lawsuit by his former research assistant Yusoff Rawther who accused him of alleged sexual assault in 2018 at the PKR party office. Former de facto law minister Datuk Zaid Ibrahim who was at Justice Roz Mawar's court yesterday (June 4) afternoon said he left the venue 'fully satisfied'. 'Her dismissal of Anwar's attempt to delay the hearing of Yusoff's civil claim of sexual assault is 100% correct,' the founder of one of Malaysia's largest legal firms, Zaid Ibrahim & Co, penned on X. I was in Justice Roz Mawar's court this afternoon, and I left fully satisfied. Her dismissal of Anwar Ibrahim's attempt to delay the hearing of Yusof's Lawther civil claim of sexual assault is hundred per cent correct I always find her judgement sound ( except one), and she is… — Zaid Ibrahim (@zaidibrahim) June 4, 2025 'I always find her judgement sound (except one) and she is undoubtedly one of our best judges.' In dismissing Anwar's application to refer eight legal questions arising from a civil suit filed by Yusoff to the Federal Court, Justice Roz Mawar ruled that the questions posed by PMX failed to cross the threshold set out in Section 84 of the Courts of Judicature Act 1964. 'None of the articles cited in the Federal Constitution – as argued by the defendant's lawyers – gave rise to any real, substantial and justiciable questions of law that require a determination by the Federal Court,' she deduced. In rejecting an application by Anwar's lawyer, Alan Wong, for a stay pending appeal on grounds that 'sorry, my hands are tied', Justice Roz Mawar said the trial of Yusoff Rawther's suit will begin at 9am on June 16 as scheduled. She further ordered PMX to pay RM20,000 in costs to Yusoff. In summing up, the opposition-slant Zaid now hopes that PMX will not proceed with the application to stay the proceeding which has been set for hearing on June 16 because there are no merits to his application. 'Furthermore, his lawyer had stated in open court that his client was ready to proceed with the trial. Why the need for deferment?' asked the former defence counsel of now incarcerated former premier Datuk Seri Najib Razak. 'As the leader of the Reformasi movement in the country, it does not look good for the PM to be seen as avoiding his accuser in (an) open court. After all, he had said on many occasions (that) the accusations were frivolous and untrue.' 'Beauty with brain' Commenting on the KL High Court declining his application to refer eight constitutional questions to the Federal Court under Article 128(2) of the Federal Constitution, Anwar reiterated that the matter has never been about seeking personal immunity or escaping legal scrutiny. 'It concerns the integrity of our constitutional system and the need to ensure that high public office is protected from litigation that may be strategically timed, politically motivated or institutionally disruptive,' argued PMX in a statement. STATEMENT ON HIGH COURT DECISION AND CONSTITUTIONAL REFERENCE This afternoon, the High Court declined my application to refer 8 constitutional questions to the Federal Court under Article 128(2) of the Federal Constitution. This matter has never been about seeking personal… — Anwar Ibrahim (@anwaribrahim) June 4, 2025 'I remain fully committed to the rule of law, the independence of our courts and the dignity of democratic governance. The legal process will continue, and I'll continue to discharge my responsibilities without distraction or compromise.' Meanwhile human rights activist and lawyer Siti Kasim described Justice Roz Mawar who was appointed as a High Court judge on Nov 12 last year as a 'beauty with brain' after having read her grounds of judgment. 'It's not only that she's pretty and beautiful but she's also very smart … Her decision is solid-molid [sic],' reacted the Orang Asli advocate with a caveat. 'Perhaps Yusoff Rawther will have his day in court, perhaps not because PMX's clever lawyers may appeal and then ask for stay although Justice Roz Mawar has insisted that the case will go on as scheduled on June 16. 'But still, I've strong feeling that the Court of Appeal shall uphold the judgment of Justice Roz Mawar because there's no other way for them to go around it; after all, her explanation is so detailed … Reading a solid judgment coming from a clever judge feels like reading a good book. 'Anyway, good luck to both Yusoff Rawther and PMX. May the righteous party win the case.' – June 5, 2025 Main image credit: SK Studio/YouTube; Suruhanjaya Pelantikan Kehakiman
Hamilton Spectator
16-05-2025
- Business
- Hamilton Spectator
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) — Spectral Medical Inc. ('Spectral' or the 'Company') (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New York. Investors interested in scheduling a meeting with the Company's management team should contact their H.C. Wainwright representative or email meetings@ . About Spectral Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively over 360,000 times to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year. The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis . The trial methods are detailed in ' Bayesian methods: a potential path forward for sepsis trials '. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit Forward-looking statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For further information, please contact:
